Qualigen Therapeutics (QLGN) Competitors $3.26 0.00 (-0.03%) Closing price 07/3/2025 03:10 PM EasternExtended Trading$3.26 0.00 (-0.09%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QLGN vs. PHXM, AIMD, CSCI, TRIB, GLYC, NKGN, KPRX, BTAI, BCLI, and SNSEShould you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include PHAXIAM Therapeutics (PHXM), Ainos (AIMD), COSCIENS Biopharma (CSCI), Trinity Biotech (TRIB), GlycoMimetics (GLYC), NKGen Biotech (NKGN), Kiora Pharmaceuticals (KPRX), BioXcel Therapeutics (BTAI), Brainstorm Cell Therapeutics (BCLI), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical products" industry. Qualigen Therapeutics vs. Its Competitors PHAXIAM Therapeutics Ainos COSCIENS Biopharma Trinity Biotech GlycoMimetics NKGen Biotech Kiora Pharmaceuticals BioXcel Therapeutics Brainstorm Cell Therapeutics Sensei Biotherapeutics Qualigen Therapeutics (NASDAQ:QLGN) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings. Which has better earnings & valuation, QLGN or PHXM? PHAXIAM Therapeutics has lower revenue, but higher earnings than Qualigen Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQualigen Therapeutics$4.98M1.07-$13.42MN/AN/APHAXIAM TherapeuticsN/AN/A-$240KN/AN/A Do institutionals & insiders hold more shares of QLGN or PHXM? 3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, QLGN or PHXM? Qualigen Therapeutics has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the S&P 500. Is QLGN or PHXM more profitable? Company Net Margins Return on Equity Return on Assets Qualigen TherapeuticsN/A N/A N/A PHAXIAM Therapeutics N/A N/A N/A Does the media refer more to QLGN or PHXM? In the previous week, PHAXIAM Therapeutics had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for PHAXIAM Therapeutics and 0 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score. Company Overall Sentiment Qualigen Therapeutics Neutral PHAXIAM Therapeutics Neutral SummaryPHAXIAM Therapeutics beats Qualigen Therapeutics on 4 of the 6 factors compared between the two stocks. Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QLGN vs. The Competition Export to ExcelMetricQualigen TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.35M$2.41B$5.49B$9.01BDividend YieldN/A1.77%5.38%4.09%P/E RatioN/A8.9827.4220.26Price / Sales1.07669.90407.97121.21Price / CashN/A157.0736.6357.47Price / Book-0.164.638.085.67Net Income-$13.42M$31.34M$3.16B$248.47M7 Day Performance-8.69%3.25%2.81%3.29%1 Month Performance-18.12%6.80%3.68%5.19%1 Year Performance-62.86%1.89%35.29%21.35% Qualigen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QLGNQualigen TherapeuticsN/A$3.260.0%N/A-62.9%$5.35M$4.98M0.0050PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049AIMDAinos0.854 of 5 stars$0.50-1.7%N/A-30.0%$10.49M$20K-0.3940CSCICOSCIENS BiopharmaN/A$3.36+1.8%N/AN/A$10.38M$9.59M-0.5820TRIBTrinity Biotech0.4131 of 5 stars$0.55-2.6%N/A-65.6%$10.25M$61.56M-0.20480Gap UpGLYCGlycoMimetics1.2243 of 5 stars$0.16-6.6%N/A-99.4%$10.00M$10K-0.3450High Trading VolumeNKGNNKGen BiotechN/A$0.22-11.0%N/A-77.3%$10.00M$80K-0.04N/AKPRXKiora Pharmaceuticals2.3393 of 5 stars$3.13-2.2%$10.00+219.5%-33.9%$9.74M$16.02M-1.0810BTAIBioXcel Therapeutics4.3275 of 5 stars$1.65+3.1%$42.60+2,481.8%-88.7%$9.69M$2.27M-0.1290Gap UpBCLIBrainstorm Cell Therapeutics4.1306 of 5 stars$1.19-2.5%$30.00+2,421.0%-77.8%$9.69MN/A-0.3540Gap DownSNSESensei Biotherapeutics4.2241 of 5 stars$8.06+5.2%$90.00+1,016.6%-27.1%$9.65MN/A-0.3540Gap Down Related Companies and Tools Related Companies PHXM Competitors AIMD Competitors CSCI Competitors TRIB Competitors GLYC Competitors NKGN Competitors KPRX Competitors BTAI Competitors BCLI Competitors SNSE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QLGN) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
